# Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct05462613/  
OnCo record `nct05462613` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of regorafenib, aspirin and bevacizumab (glioblastoma use) in colorectal cancer, run by Centre Hospitalier Universitaire de Besancon, now recruiting.

## Summary

Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer is a phase 2/3, randomised interventional study registered as NCT05462613 by Centre Hospitalier Universitaire de Besancon, with a registry enrolment figure of 446 participants, started 2023-05-09 and due to reach its primary completion in 2029-11. Interventions recorded: quality of life questionnaires; Blood sample; Regorafenib; Metronomic chemotherapies; Aspirin; Bevacizumab; FOLFIRI or FOLFOX. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: best objective response during treatment period (phase II); overall survival (OS) (phase III). Colorectal eligibility wording from the registry: "Patients with histologically proven metastatic colorectal cancer in progression after a first line of chemotherapy +/- targeted therapy". Sites: France. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: REPROGRAM-02
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05462613
- Phase: 2/3
- Setting: Induction Regorafenib in Combination With Metronomic Cyclophosphamide, Capecitabine, and Low-dose Aspirin Followed by Chemotherapy in Second Line Metastatic Colorectal Cancer Carcinoma An Open-label Randomized Phase II-III Study
- Sponsor: Centre Hospitalier Universitaire de Besancon
- Enrolled: 446

## Sources

- ClinicalTrials.gov NCT05462613: https://clinicaltrials.gov/study/NCT05462613

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Aspirin](https://onco.cc/drugs/aspirin/), [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [Regorafenib](https://onco.cc/drugs/regorafenib/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05462613.json